{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T02:21:31Z","timestamp":1769480491372,"version":"3.49.0"},"reference-count":39,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Comprehensive genomic profiling (CGP) is a tool used in precision oncology to identify genomic alterations and match them with targeted therapies across several tumor types. However, real-world data on its clinical utility and impact remains limited. The FRONTAL study (Foundation Medicine Real wOrld evideNce in porTugAL) is a multicenter academic initiative that established a national registry of Portuguese patients with solid tumors who underwent CGP with FoundationOne CDx, Liquid CDx or FoundationOne Heme assays. Methods: Eligible patients had advanced solid tumors not suitable for curative treatment at the time of recruitment. Prior CGP testing was permitted if taken within 12 months before study initiation. Genomic profiling data were extracted from FoundationOne Medicine reports, and clinical information was extracted from medical records. Actionable alterations were defined as those associated with approved treatments or with clinical evidence of benefit in other cancers, per NCCN guidelines. Variant interpretation was also reviewed according to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) guidelines. The primary outcome was disease control at 16 weeks, defined by the absence of progression. Results: The study included 205 patients between 2020 and 2025 across 10 sites, with colorectal (40, 19.5%), sarcomas (28, 13.7%), and other gastrointestinal tumors (22, 10.7%) being the most common pathologies. Actionable alterations were identified in 104 cases (50.7%). Genomic findings guided therapy decisions in 50 patients (24.4%), of whom 30 achieved disease control at 16 weeks (14.6%). Conclusions: The FRONTAL study highlighted the clinical relevance of CGP in advanced solid tumors. Over half of the patients had actionable alterations, a quarter had therapy changes based on CGP results, and improved disease outcome was observed in approximately 15% of the cohort.<\/jats:p>","DOI":"10.3390\/curroncol33020066","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T15:48:30Z","timestamp":1769442510000},"page":"66","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the Impact of Comprehensive Genomic Profiling on Therapeutic Selection for Advanced Solid Tumors in Portugal"],"prefix":"10.3390","volume":"33","author":[{"given":"Nuno","family":"Tavares","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-7621","authenticated-orcid":false,"given":"Pedro","family":"Sim\u00f5es","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade Loures-Odivelas, 2674-514 Loures, Portugal"}]},{"given":"Raquel","family":"Lopes-Br\u00e1s","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade Santa Maria, 1649-035 Lisboa, Portugal"}]},{"given":"Teresa R.","family":"Pacheco","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade Santa Maria, 1649-035 Lisboa, Portugal"},{"name":"Gulbenkian Institute for Molecular Medicine, 1649-028 Lisboa, Portugal"},{"name":"Faculty of Medicine, University of Lisbon, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal"}]},{"given":"Sara","family":"Damaso","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade Santa Maria, 1649-035 Lisboa, Portugal"}]},{"given":"Andre","family":"Mansinho","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade Santa Maria, 1649-035 Lisboa, Portugal"},{"name":"Gulbenkian Institute for Molecular Medicine, 1649-028 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7657-0902","authenticated-orcid":false,"given":"Leonor Abreu","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade Santa Maria, 1649-035 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1127-052X","authenticated-orcid":false,"given":"Gon\u00e7alo","family":"Nogueira-Costa","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade Santa Maria, 1649-035 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3558-3966","authenticated-orcid":false,"given":"Catarina","family":"Abreu","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade Santa Maria, 1649-035 Lisboa, Portugal"}]},{"given":"Tiago","family":"Barroso","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade Santa Maria, 1649-035 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3663-4801","authenticated-orcid":false,"given":"Nuno","family":"Bonito","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Coimbra Francisco Gentil, 3000-075 Coimbra, Portugal"}]},{"given":"Rita","family":"Figueir\u00f3","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Coimbra Francisco Gentil, 3000-075 Coimbra, Portugal"}]},{"given":"Bogdana","family":"Darmits","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Coimbra Francisco Gentil, 3000-075 Coimbra, Portugal"}]},{"given":"Sara Loureiro","family":"Melo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Coimbra Francisco Gentil, 3000-075 Coimbra, Portugal"}]},{"given":"Tania","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital da Luz, 1500-650 Lisboa, Portugal"}]},{"given":"Helena","family":"Guedes","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade de Gaia e Espinho, 4434-502 Vila Nova de Gaia, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9635-4505","authenticated-orcid":false,"given":"Edgar","family":"Pratas","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade de Coimbra, 3004-561 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1377-3032","authenticated-orcid":false,"given":"Diogo Alpuim","family":"Costa","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, CUF Oncologia, 1998-018 Lisboa, Portugal"},{"name":"Oncology Functional Unit, Hospital de Cascais, 2755-009 Alcabideche, Portugal"}]},{"given":"Frederico Ferreira","family":"Filipe","sequence":"additional","affiliation":[{"name":"Oncology Functional Unit, Hospital de Cascais, 2755-009 Alcabideche, Portugal"}]},{"given":"Daniela","family":"Macedo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Lus\u00edadas, 1500-458 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0642-1979","authenticated-orcid":false,"given":"Ana","family":"Cavaco","sequence":"additional","affiliation":[{"name":"Gulbenkian Institute for Molecular Medicine, 1649-028 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4190-5554","authenticated-orcid":false,"given":"Marina","family":"Pavanello","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade Santa Maria, 1649-035 Lisboa, Portugal"},{"name":"Gulbenkian Institute for Molecular Medicine, 1649-028 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4782-7318","authenticated-orcid":false,"given":"Luis","family":"Costa","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade Santa Maria, 1649-035 Lisboa, Portugal"},{"name":"Gulbenkian Institute for Molecular Medicine, 1649-028 Lisboa, Portugal"},{"name":"Faculty of Medicine, University of Lisbon, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cell.2016.12.015","article-title":"Implementing Genome-Driven Oncology","volume":"168","author":"Hyman","year":"2017","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Milbury, C.A., Creeden, J., Yip, W.K., Smith, D.L., Pattani, V., Maxwell, K., Sawchyn, B., Gjoerup, O., Meng, W., and Skoletsky, J. (2022). Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264138"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Woodhouse, R., Li, M., Hughes, J., Delfosse, D., Skoletsky, J., Ma, P., Meng, W., Dewal, N., Milbury, C., and Clark, T. (2020). Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237802"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: A report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Delord","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/annonc\/mdz080","article-title":"Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: Analysis from the ProfiLER trial","volume":"30","author":"Wang","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1200\/JCO.19.03010","article-title":"Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)","volume":"38","author":"Flaherty","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00122","article-title":"Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study","volume":"2","author":"Mangat","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kringelbach, T., H\u00f8jgaard, M., Rohrberg, K., Spanggaard, I., Laursen, B.E., Ladekarl, M., Haslund, C.A., Harsl\u00f8f, L., Belcaid, L., and Gehl, J. (2023). ProTarget: A Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling\u2014A national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10632-9"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","article-title":"The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs","volume":"574","author":"Hoes","year":"2019","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/jnci\/djaf015","article-title":"Comprehensive genome profiling for treatment decisions in patients with metastatic tumors: Real-world evidence meta-analysis and registry data implementation","volume":"117","author":"Zerdes","year":"2025","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2200715","DOI":"10.1200\/PO.22.00715","article-title":"Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer","volume":"7","author":"Gibbs","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1093\/oncolo\/oyad251","article-title":"Insights of Clinical Significance From 109\u2009695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles","volume":"29","author":"Heilmann","year":"2024","journal-title":"Oncologist"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gremke, N., Rodepeter, F.R., Teply-Szymanski, J., Griewing, S., Boekhoff, J., Stroh, A., Tarawneh, T.S., Riera-Knorrenschild, J., Balser, C., and Hattesohl, A. (2024). NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors-A Retrospective Molecular Tumor Board Analysis. Cancers, 16.","DOI":"10.3390\/cancers16081561"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bruzas, S., Kuemmel, S., Harrach, H., Breit, E., Ataseven, B., Traut, A., R\u00fcland, A., Kostara, A., Chiari, O., and Dittmer-Grabowski, C. (2021). Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice. Cancers, 13.","DOI":"10.3390\/cancers13184564"},{"key":"ref_20","first-page":"djv332","article-title":"Prospective Clinical Study of Precision Oncology in Solid Tumors","volume":"108","author":"Sohal","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2020.04.019","article-title":"Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group \u2018Molecular Diagnostics and Therapy\u2019","volume":"135","author":"Westphalen","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"12742","DOI":"10.1038\/s41598-023-39608-2","article-title":"Mutational landscape of cancer-driver genes across human cancers","volume":"13","author":"Sinkala","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e36550","DOI":"10.1016\/j.heliyon.2024.e36550","article-title":"Mutation patterns in colorectal cancer and their relationship with prognosis","volume":"10","author":"Su","year":"2024","journal-title":"Heliyon"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41392-021-00647-8","article-title":"Molecular mechanisms underpinning sarcomas and implications for current and future therapy","volume":"6","author":"Damerell","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1038\/s41467-018-06146-9","article-title":"Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490, 61\u201370.","DOI":"10.1038\/nature11412"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"Ahmed","year":"2010","journal-title":"J. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"19261","DOI":"10.1038\/s41598-021-98527-2","article-title":"TP53 mutants and non-HPV16\/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer","volume":"11","author":"Kuno","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1368-8375(02)00163-X","article-title":"The p53 network in head and neck cancer","volume":"39","author":"Gasco","year":"2003","journal-title":"Oral Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ofner, H., Kramer, G., Shariat, S.F., and Hassler, M.R. (2025). TP53 Deficiency in the Natural History of Prostate Cancer. Cancers, 17.","DOI":"10.3390\/cancers17040645"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"McLendon","year":"2008","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","article-title":"Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies","volume":"1","author":"Ross","year":"2015","journal-title":"JAMA Oncol"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1073\/pnas.97.7.3352","article-title":"APC mutations in sporadic colorectal tumors: A mutational \u201chotspot\u201d and interdependence of the \u201ctwo hits\u201d","volume":"97","author":"Rowan","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Saoudi Gonzalez, N., Patelli, G., and Crisafulli, G. (2025). Clinical Actionability of Genes in Gastrointestinal Tumors. Genes, 16.","DOI":"10.3390\/genes16101130"},{"key":"ref_36","unstructured":"(2023). Utiliza\u00e7\u00e3o de Testes Gen\u00f3micos no Apoio \u00e0 Decis\u00e3o Terap\u00eautica em Oncologia, Ordem dos M\u00e9dicos."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41698-025-00858-0","article-title":"A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer","volume":"9","author":"Volders","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Bogas, M., Antas, J., Magalh\u00e3es, C., Revige, M., Guerra, L., Ribeiro, C., E\u00e7a, R.C., Nunes, F., Lopes, A., and Costa, L. (2025). Assessment of competencies of clinical research professionals and proposals to improve clinical research in Portugal. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1578955"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e2323336","DOI":"10.1001\/jamanetworkopen.2023.23336","article-title":"First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities","volume":"6","author":"Matsubara","year":"2023","journal-title":"JAMA Netw. Open"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/66\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T16:11:59Z","timestamp":1769443919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/66"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["curroncol33020066"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33020066","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}